Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13534002 | 0.91 | OPRM1 (0.52) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL22782241 | 0.87 | OPRM1 (0.51) | OPRM1OPRD1OPRK1CACNA1C | |
| SCHEMBL6045574 | 0.85 | OPRM1 (0.54) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL13451313 | 0.85 | CACNA1C (0.71) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL14355475 | 0.84 | CACNA1C (0.58) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL22634131 | 0.74 | OPRM1 (0.71) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL13534166 | 0.70 | OPRM1 (0.52) | OPRM1OPRD1OPRK1CACNA1C | |
| SCHEMBL3303683 | 0.70 | OPRM1 (0.80) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL821488 | 0.69 | OPRM1 (0.78) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL11563541 | 0.69 | OPRM1 (0.82) | OPRM1OPRD1OPRK1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643704-B1 | NEW INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | HAMELN PHARMA GMBH (DE) | 2020-12-16 | — | — | EP | disclosed |
| EP-3643704-B1 | NEW INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | HAMELN PHARMA GMBH (DE) | 2020-12-16 | — | — | EP | disclosed |
| US-10844014-B2 | Intermediates for the preparation of remifentanil hydrochloride | HAMELN PHARMA GMBH (DE) | 2020-11-24 | — | — | US | disclosed |
| US-10844014-B2 | Intermediates for the preparation of remifentanil hydrochloride | HAMELN PHARMA GMBH (DE) | 2020-11-24 | — | — | US | disclosed |
| US-20200131127-A1 | INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | HAMELN PHARMA PLUS GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| US-20200131127-A1 | INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | HAMELN PHARMA PLUS GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| EP-3643704-A1 | NEW INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | hameln pharma plus gmbh (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643704-A1 | NEW INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | hameln pharma plus gmbh (DE) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844014-B2 | Intermediates for the preparation of remifentanil hydrochloride | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-20200131127-A1 | INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.